Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Molly Z Karlinsey"'
Autor:
Brandon G Santiago, Stephen H Eisennagel, Gregory E Peckham, Amanda M Liebhardt, Chad L Alburn, Theresa J Roethke, Michael A Reilly, Jens R Sydor, Molly Z Karlinsey
Publikováno v:
Bioanalysis. 15:177-191
As the desire for a shortened design/make/test/learn cycle increases in early drug discovery, the pressure to rapidly deliver drug metabolism pharmacokinetic data continues to rise. From a bioanalytical standpoint, in vitro assays are challenging bec
Autor:
Yinghe Brenda Li, Andrew P Mayer, John F. Kellie, Caroline J. Sychterz, Kristen E. Pannullo, Matthew Szapacs, Kristy J Fraley, Molly Z Karlinsey
Publikováno v:
Analytical chemistry. 92(12)
Complex biotherapeutics present challenges from drug discovery, screening, and development perspectives. While monoclonal antibody drugs are not monitored for metabolites in the same manner as small molecules, biotherapeutics such as fusion proteins,
Publikováno v:
Analytical Methods. 8:3023-3033
Carbohydrate analysis poses many analytical challenges, in terms of extraction, chromatographic separation, and detection. Extraction challenges are associated with poor recovery from biological matrices using conventional techniques such as protein
Autor:
Molly Z Karlinsey, John F. Kellie
Publikováno v:
Bioanalysis.
Biotherapeutic drugs have emerged in quantity in pharmaceutical pipelines, and increasingly diverse biomolecules are progressed through preclinical and clinical development. As purification, separation, mass spectrometer detection and data processing
Autor:
Shing H. Mai, Sarah L. Childs, Robert A. Biddlecombe, Molly Z Karlinsey, John R. White, John F. Kellie, Shugui Chen, Andrew S. Thomson
Publikováno v:
Journal of pharmaceutical sciences. 108(4)
Biotransformation monitoring involves tracking drug modification occurring during in-life studies. Critical Quality Attribute monitoring from forced degraded drug material or in-life sample sets can provide an in-depth assessment of product quality f
Publikováno v:
Bioanalysis. 10(4)
Aim: GSKA is a compound that was in development in clinical trials. A bioanalysis method to quantify GSKA using volumetric absorptive microsampling (VAMS) was developed and hematocrit (HCT) related assay bias was investigated. Methodology: After accu
Publikováno v:
Bioanalysis. 9(23)
Aim: Typically, quantitation of biotherapeutics from biological matrices by LC–MS is based on a surrogate peptide approach to determine molecule concentration. Recent efforts have focused on quantitation of the intact protein molecules or larger ma
Autor:
Michael S. Forbes, Timothy L. Macdonald, Preeti Chhabra, Lisa A. Palmer, Victor E. Laubach, Allan Doctor, Benjamin Gaston, Molly Z. Karlinsey, Mary Lynn Sheram
Publikováno v:
Journal of Clinical Investigation. 117:2592-2601
NO transfer reactions between protein and peptide cysteines have been proposed to represent regulated signaling processes. We used the pharmaceutical antioxidant N-acetylcysteine (NAC) as a bait reactant to measure NO transfer reactions in blood and
Autor:
Esaie Pierre, Christopher A. Evans, Chester L. Bowen, Hermes Licea-Perez, Alan H. Stokes, Joseph Siple, Kristen E Jurusik, Molly Z Karlinsey, Neil Spooner, Jim Kenney
Publikováno v:
Bioanalysis. 5(9)
Background: A novel device and procedure for the collection and isolation of microvolumes of plasma have been developed and two pilot rodent PK studies have been completed. Results: This method involves collection of blood into a plastic-wrapped, EDT